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EDITORIAL COMMENT
Dilate or Defer?
View of a Skeptic*
Spencer B. King III, MD, MACC
Atlanta, Georgia
Coronary angioplasty was developed by Andreas Gruentzig
as a less invasive method to alleviate ischemia and the
debilitating angina it causes. The introduction of balloon
dilation and the subsequent improvements, especially stent-
ing, is a resounding success story in medicine. Bypass
surgery has been safely avoided as demonstrated in many
randomized trials. Although subsets of patients with exten-
sive disease, especially those with diabetes, have fared better
with surgery, angioplasty and stenting have far surpassed
surgery as the most frequently performed revascularization
procedures.
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Many patients with coronary artery disease do not have
debilitating symptoms, and the data to support revascular-
ization in these have undergone less scrutiny. The absence
of severe symptoms does not assure a good prognosis, and
the extent of coronary artery disease, the magnitude of
ischemia, and left ventricular function define patients who
have an improved prognosis with surgery and probably (by
inference) percutaneous intervention. There are, however,
many patients without refractory symptoms who lack the
prognostic indicators mandating revascularization. Many of
these are undergoing percutaneous interventions all over the
world and, yet, evidence for the true value of that approach
has been sparse.
The Randomized Treatment of Angina (RITA)-2 trial
was designed to compare the strategy of performing percu-
taneous transluminal coronary angioplasty (PTCA) or med-
ical therapy alone on patients who were judged eligible for
either approach. The primary end point was death or
myocardial infarction (MI) at five years. In this issue of the
Journal, Henderson et al. (1) report the results: the primary
end point, death or MI, was not different, and death alone
was not different (43 in each group). The need for subse-
quent bypass surgery was not different. Repeat percutaneous
intervention was more in the patients who did not receive it
in the first place, but that difference was not great, 17% of
the medical group and 27% in the PTCA group at five years.
Subsequent revascularization (percutaneous coronary inter-
vention [PCI] or coronary artery bypass grafting [CABG])
was used in 23.3% of the PTCA and 28.8% of the surgery
patients. As reported by Henderson et al. (1), angina was
improved, especially during the first year; however, that
difference narrowed over time due to the performance of
PCI in symptomatic patients in the medical group. Why
was the outcome so disappointing for PTCA? Many will
dismiss this study as dated. “It is so 90s.” This may be true.
Let this skeptic examine the evidence.
The skeptic: “This is a low-risk group.” The overall
mortality at five years of 4.6% in the PTCA group and 4.7%
in the medical group would not argue for an abundance of
high-risk features. Sixty percent of the patients had single-
vessel disease at baseline. The National Heart, Lung, and
Blood Institute Dynamic registry of PCI in high volume
centers was composed of one-vessel disease (40.6%), two-
vessel disease (32.3%), and three-vessel (26.8%), and a
single lesion was treated in 68.2% of these cases (2). So, are
the lesions treated in this study markedly different from
those in elective patients, without the exclusions listed in
this trial, who are undergoing PCI today? I suspect not.
The skeptic: “This is old technology, results would be
much better today.” Stenting was used in this trial only to
bail out complications of PTCA. Emergency surgery was
used in 1.5% (7 of 471), which is not an unusually high
number even in the stent era. In the NHLBI Dynamic
registry, it has been 1.1% (2).
The skeptic: “Surely stenting has a better outcome than
plain old balloon angioplasty.” The findings of a recent
meta-analysis of 29 trials of routine stenting versus balloon
angioplasty and stenting only for complications or residual
stenosis may be surprising. Death, death or MI, and
subsequent coronary bypass surgery were not different (3).
Repeat PCI was more common in the balloon angioplasty
with provisional stenting group, but the absolute difference
was only 5 patients per 100 treated. Stenting was used more
commonly in the control group in these trials, but the
almost identical death, MI, and CABG rates by treatment
group are reminiscent of the present study. Routine stenting
may have changed the primary outcome of this trial, but the
evidence to assume that is lacking.
The skeptic: “English patients will put up with anything.”
American colleagues may feel that the subjects of this trial
will keep the proverbial “stiff upper lip” and que passively for
staggering doses of anti-anginal medications to combat their
angina. (English colleagues in turn may feel that Americans
have the “princess and the pea” syndrome and will be dilated
at the slightest twinge or any hint of ischemia). Medical
systems are different, but the consumption of antianginals
was not dramatically different between these treatment
groups. At all time points there was more angina in the
medical group, and this may have been reduced by more
aggressive interventions. However, the absence of more
interventions in the medical group did not seem to adversely
affect the primary end point of death or MI.
The skeptic: “It is true that the use of beta-blockers,
angiotensin-converting enzyme inhibitors, lipid-lowering
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agents, and thianopyridines seem very low by current
standards.” These agents exert their beneficial effect primar-
ily over the extended follow-up and would be expected to
benefit the medical group as well as the PTCA group. Only
glycoprotein IIb/IIIa agents have been shown to reduce
periprocedural MI significantly. Routine biomarkers were
not obtained in this study, but the occurrence of periproce-
dural MI, although small, did not translate into an increase
in late events.
The skeptic: “Let’s get back to the angina. At the end of
the follow-up, grade II or more angina was present in 21.4%
of the medical patients but only 15.0% of the PTCA group.
(6.4%; 95% confidence interval, 1.5 to 11.3; p  0.011).
That is about a 30% reduction in angina.” Of course, for
patients with a less stiff upper lip, an intervention could be
done.
The skeptic: “At least they could exercise more.” Yes, 25 s
more at 3 years!
This skeptic is beginning to run out of ammunition.
Maybe the Clinical Outcome Utilizing Revascularization
and Aggressive drug Evaluation (COURAGE) trial and the
Bypass Angioplasty Revascularization Investigation-2 Dia-
betes (BARI 2D) will come to my rescue at least in some
subsets, like diabetes (only 9% of the patients in this trial
had treated diabetes).
What can we learn from this trial that can be applied to
the next patient we see? As the authors point out, if there is
no evident prognostic marker that the patient is at increased
risk, then use revascularization to solve refractory symptoms.
This will vary among patients. Some will have a strong
desire to avoid angina so as to engage in vigorous activities.
Others will be intolerant of beta-blockers. We must, how-
ever, be honest with ourselves as well as our patients. If
prognosis is not an issue, that should be clearly stated.
Physicians have been accused of having the “oculostenotic
reflex.” Patients who are told that they have a “blockage”
often have an “auditorystenotic reflex.” “If it is blocked, I
want it fixed.” If there is no evidence to support improve-
ment in prognosis, the patient needs to hear and understand
that. Then, if the symptoms warrant an intervention, the
patient can help make the decision.
In the coming era of drug-eluting stents, the cost to the
medical system will increase. Physicians must evaluate this
advance for its contribution to preventing the hard end
points of death and MI. Industry and payors must provide
a balance in pricing and reimbursement for all patients who
require revascularization. Cost containment can be achieved
by avoiding intervention in those who do not. RITA-2
supports what we all should know and practice.
Reprint requests and correspondence: Dr. Spencer B. King III,
Fuqua Heart Center, Ste. 2075, 95 Collier Road NW, Atlanta,
Georgia 30309. E-mail: sking@acri.com.
REFERENCES
1. Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in
the RITA-2 trial: coronary angioplasty versus medical therapy. J Am
Coll Cardiol 2003;42:1161–70.
2. The NHLBI Dynamic Registry Investigators Meeting. Chicago, IL:
March, 2003.
3. Brophy JM, Belisle P, Joseph L. The evidence for coronary stents—a
hierarchical Bayesian meta-analysis. Ann Intern Med 2003. In Press.
1172 King III JACC Vol. 42, No. 7, 2003
Editorial Comment October 1, 2003:1171–2
